Immunocore signs research and licensing agreement with GlaxoSmithKline

15 July 2013 at 11:00 AM EDT
PDF Version

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, today announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year.

Please click on the link below to download the full Press Release: